We’re pleased to announce that PHARMAC has approved the use of the Exceptional Circumstances framework to provide funding of vitamin A oral liquid for a targeted group of patients.
We are seeking feedback on a proposal to fund mepolizumab (Nucala), a new treatment for severe refractory eosinophilic asthma, from 1 April 2020 through a provisional agreement with GlaxoSmithKline NZ Limited (GSK).
Response to a request for data on fingolimod and other medicines.
Response to a request for information about PHARMAC's contingency plans around the lamotrigine brand change.
Response to a request for information on asthma inhalers data.
Response to an Official Information Act request for data on sex change hormones for males.
To help make our decision-making process clearer, we are seeking feedback on a proposal for PHARMAC to make decisions to decline specified inactive funding applications.
Response to an Official Information Act for information related to the lamotrigine NPPA access widening.
PHARMAC has published the Rare Disorders Subcommittee meeting records which recommends Spinraza (nusinersen), a medication for spinal muscular atrophy, is funded in New Zealand.
We are seeking feedback on a proposal to widened funded access to lenalidomide (Revlimid) to include maintenance treatment for people with newly diagnosed multiple myeloma (a type of blood cancer) who have undergone autologous stem cell transplant (auto-SCT), through a provisional agreement with Celgene Pty Limited.
Closes: 5pm, Friday 17 January 2020.
PHARMAC has made a decision to make changes to the funded brands of fluticasone and fluticasone with salmeterol metered dose inhalers (MDIs), which are used in the management of asthma and chronic obstructive pulmonary disease (COPD).
Decision to change the sole subsidised brand of lidocaine [lignocaine] hydrochloride gel 2%, urethral syringe
The funded brand of lidocaine [lignocaine] hydrochloride gel 2%, urethral syringe will change from Cathejell to Instillagel Lido.
Response to an Official Information Act request for communications between PHARMAC and Sanofi, on compassionate supply.
Response to a request for information for data on nivolumab and pembrolizumab Special Authorities, for July, August and September 2019.
Response to a request for information about communications around the Northland meningitis outbreak.
PHARMAC are pleased to announce changes to the funding of apomorphine hydrochloride, a medicine used to treat advanced Parkinson’s disease, through an agreement with Stada.
We are pleased to announce the approval of a listing agreement with O&M Halyard Australia Limited for listing of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020.
Decision to list medical devices in the interventional radiology category supplied by Becton Dickinson Limited
We are pleased to announce the approval of a listing agreement with Becton Dickinson Limited for the supply of interventional radiology medical devices to DHBs.
PHARMAC are seeking feedback on proposals to widen funded access to medicines in the blood, alimentary and immunosuppressant therapy areas.
Closes: 4pm Monday, 6 January 2020.
We are pleased to announce the approval of a listing agreement with New Zealand Medical & Scientific Limited for the supply of obstetrics and gynaecology products to DHBs.